“27 Table of Contents Net cash used in investing activities was $0.5 million during the three months ended March 31, 2025 and primarily consisted of capital expenditures of $13.5 million, partially offset by $13.0 million in proceeds from maturities of marketa…”10-Q · May 6, 2026 ↗
Penumbra, Inc.
PEN
Market read
Penumbra, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 26 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.
- PEN's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if PEN's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 26 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- PEN's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
- Latest annual revenue changed +17.5% year over year.
- Operating margin changed +12.7 percentage points in the latest annual period.
- Net margin changed +11.5 percentage points in the latest annual period.
No qualifying adverse evidence was identified; that is not proof there is no downside.
- P/E is 46% above the available filing-peer median; determine whether growth and quality justify the difference.
- EV/sales is 138% above the available filing-peer median; determine whether growth and quality justify the difference.
Price as of Sep 10, 2026
317.80Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
Persistent and emerging business drivers
“As a result of this assessment, the Company estimated that the fair value of the asset group was zero and the Company recorded a pre-tax impairment charge of $ 76.9 million during the three months ended June 30, 2024, which was comprised of $ 58.9 million in…”10-K · Feb 25, 2026 ↗
“The Merger is expected to close by the end of 2026, subject to customary closing conditions, including approval by our stockholders and regulatory approvals.”10-Q · May 6, 2026 ↗
“The increase was primarily due to a $1.6 million increase in personnel-related expenses, partially offset by a $1.3 million decrease in other research and development activities primarily related to product development due to the timing of planned investments.”10-Q · May 6, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 8.9× · EV/sales 8.8×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:45 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for PEN. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for PEN. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind PEN
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
BSXBoston Scientific CorporationpartnerMay 6, 2026 ▾
“The increase was primarily due to a $17.2 million increase in personnel-related expenses driven by an increase in headcount and related expenses to support our growth, a $9.4 million increase in acquisition-related expenses primarily attributable to professio…”
BSXBoston Scientific CorporationcompetitorFeb 25, 2026 ▾
“Our most notable competitors are Boston Scientific, Medtronic, Stryker (now including Inari Medical), Terumo and several private companies.”
Depended on by
OSRHOSR Health, Inc.distributorMar 31, 2026 ▾
“32 Since 2015, RMC has also distributed neuro-intervention medical device equipment manufactured by Penumbra Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
PEN is currently a Follower in the organic co-movement group High-Beta Growth. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.